Related Experiment Video
Updated: Jan 8, 2026
Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus
Published on: June 17, 2015
Meprin β elevates hippocampal soluble Aβ in the APP/V717I mouse model
Maximilian Keller1, Celine Gallagher2, Liana Marengo1
1Molecular Neurodegeneration, Institute for Pathobiochemistry, University Medical Center Mainz, Mainz, Germany.
Abstract:
The emergence of Alzheimer's disease (AD) pathology has been the focus of multiple hypotheses, with amyloid β (Aβ) playing a central role due to its presence in both familial and sporadic AD. Therefore, a crucial aspect of AD research is understanding the generation of different Aβ species. Aβ peptides result from the proteolytic processing of Amyloid Precursor Protein (APP) by β- and γ-secretases, with BACE1 being the most prominent β-secretase. However, BACE1-overexpressing mouse models exhibit disadvantages, making them limited for AD research. Importantly, N-terminally truncated Aβ species, which constitute up to 70 % of Aβ in AD brains, are not generated by BACE1. In recent years, alternative proteases capable of cleaving APP have been identified, bridging the gap between N-terminally truncated Aβ species and BACE1-derived Aβ. Among these novel players, the metalloprotease meprin β has emerged as a risk factor in AD pathology, generating both N-terminally truncated and full-length Aβ species. Our primary objective was to develop a mouse model that more accurately resembles the pathology of AD beyond BACE1-overexpressing models, while simultaneously confirming APP cleavage of meprin β in the hippocampus and cerebral cortex. Overexpression of meprin β led to a marked increase in soluble Aβ levels, particularly in the hippocampus, indicating a higher vulnerability or elevated meprin β activity in this region compared to the cerebral cortex. Notably, this biochemical change occurred without any observable behavioral deficits, suggesting a region-specific role of meprin β in AD pathology that may extend beyond immediate functional impairment.
Insights
Alzheimer's disease research identified meprin beta as a key enzyme in generating amyloid-beta (Aβ) peptides. Overexpressing meprin beta in mice increased Aβ levels, especially in the hippocampus, offering a new model for Alzheimer's disease studies.
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Background:
- Alzheimer's disease (AD) pathology involves amyloid-beta (Aβ) peptides, crucial for both familial and sporadic forms.
- Understanding Aβ generation is vital, with BACE1 traditionally studied, but it doesn't produce N-terminally truncated Aβ species prevalent in AD brains.
- Alternative proteases, like meprin β, are increasingly recognized for their role in APP processing and AD pathology.
Purpose of the Study:
- To develop a more accurate mouse model for Alzheimer's disease (AD) pathology beyond BACE1-overexpressing models.
- To investigate the role of meprin β in Amyloid Precursor Protein (APP) cleavage within the hippocampus and cerebral cortex.
- To assess the impact of meprin β overexpression on Aβ generation and potential behavioral deficits.
Main Methods:
- Development of a mouse model overexpressing meprin β.
- Biochemical analysis of soluble Aβ levels in hippocampal and cerebral cortex tissues.
- Assessment of behavioral deficits in the engineered mouse model.
Main Results:
- Overexpression of meprin β significantly increased soluble Aβ levels, with a pronounced effect in the hippocampus.
- Meprin β activity appears higher or the hippocampus shows greater vulnerability compared to the cerebral cortex.
- No observable behavioral deficits were detected in mice overexpressing meprin β, despite biochemical changes.
Conclusions:
- Meprin β plays a significant role in generating Aβ species relevant to Alzheimer's disease (AD) pathology.
- The hippocampus may be particularly susceptible to meprin β-mediated Aβ production.
- This study provides a novel mouse model for AD research, highlighting a region-specific role for meprin β that warrants further investigation beyond immediate behavioral impairment.
More Related Videos
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016